Overview
Status
Active
Registry date
2022-08-01
Share capital
5,000.00 PLN
Registered address
ul. Rtm. Witolda Pileckiego 67/200, 02-781 Warszawa, Poland
Email
Financials
Filing timeliness
No financial statement for 2024 – the filing deadline has passed.
- 2024not filed
- 202326/06/2024
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2023.
Results vs industry
Revenue
This companyUSD 9.06kMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD -111.32kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 116.87kMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 3.86kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Sergiy Revin – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Diagnostics Research Laboratory - Drl Llc | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2022-10-01 to 2025-10-10.
Reason for removal: Art. 96 ust. 9 pkt 4 (taxpayer or their representative fails to appear on summons of tax authorities)
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
FAQ
The main business activity of DRL Poland focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on August 1, 2022.
The headquarters is located at: ul. Rtm. Witolda Pileckiego 67, 02-781 Warszawa.
The management board consists of: Sergiy Revin (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from August 1, 2022 to December 31, 2023.
In 2023, the company generated total revenue of $9,062.
No, in 2023 the company was not profitable, reporting a net loss of $111,324.
The largest operating cost category falls under external services. This category amounted to $60,255 in 2023, representing 52% of all operating expenses.
Last updated: 2026-10-07